Antisera from immunized animals that is purified and used as a passive immunizing
agent against specific BACTERIAL TOXINS.
https://www.ema.europa.eu/en/medicines/human/EPAR/obiltoxaximab-sfl 2020 false false false United Kingdom French English treatment outcome syndication feed summary of product characteristics package leaflet drug evaluation drug approval europe obiltoxaximab obiltoxaximab obiltoxaximab anthrax orphan drug production drug therapy, combination inhalation anthrax bacillus anthracis infusions, intravenous anthrax protective antigen product surveillance, postmarketing Post-Exposure prophylaxis adult child aged inhalation anthrax drug interactions pregnancy breast feeding drug evaluation, preclinical anthrax toxin antigens, bacterial bacterial toxins antibodies, monoclonal antitoxins antibodies, monoclonal antitoxins respiratory tract infections anthrax respiratory tract infections
--- https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00376 2018 false false false Canada French English drug information drug approval canada Anthrax Immune Globulin Intravenous Anthrax Immune Globulin Intravenous toxemia anthrax inhalation anthrax respiratory tract infections product surveillance, postmarketing drug evaluation antitoxins immunoglobulin G antitoxins immunoglobulin G